Literature DB >> 2285305

In vitro activity of BAY v 3522, a new cephalosporin for oral administration.

T L Hodges1, G M Eliopoulos, K Klimm, R C Moellering.   

Abstract

The activity of BAY v 3522 was tested against over 500 clinical bacterial isolates and compared with the activities of ampicillin, amoxicillin-clavulanate, cefaclor, cefixime, cefuroxime, cephalexin, and/or ciprofloxacin, erythromycin, and metronidazole. BAY v 3522 activity against staphylococci and streptococci equaled or exceeded those of the other agents. BAY v 3522 exhibited no significant advantage over cefaclor, cefuroxime, or cephalexin against gram-negative bacilli.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2285305      PMCID： PMC171947          DOI： 10.1128/AAC.34.9.1849

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  In vitro activity of Bay v 3522, a new cephalosporin, compared with activities of other agents.

Authors:  R Wise; J M Andrews; J P Ashby; D Thornber
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

2.  Disk diffusion susceptibility of Branhamella catarrhalis and relationship of beta-lactam zone size to beta-lactamase production.

Authors:  I Luman; R W Wilson; R J Wallace; D R Nash
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

3.  Community-acquired pneumonia due to penicillin-resistant pneumococci.

Authors:  C Feldman; J M Kallenbach; S D Miller; J R Thorburn; H J Koornhof
Journal:  N Engl J Med       Date:  1985-09-05       Impact factor: 91.245

4.  In vitro activities of ICI 194008 and ICI 193428, two new cephem antimicrobial agents.

Authors:  J D Allan; G M Eliopoulos; E Reiszner; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 5.  Antibiotic resistance in Haemophilus influenzae: epidemiology, mechanisms, and therapeutic possibilities.

Authors:  J D Williams; F Moosdeen
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec
  5 in total
  2 in total

1.  Mechanism of action of BAY v 3522, a new cephalosporin with unusually good activity against enterococci.

Authors:  G Amalfitano; A Grossato; R Fontana
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 2.  Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

Authors:  A Markham; R N Brogden
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.